Mostrar el registro sencillo del ítem

dc.contributor.authorCuesta Sancho, Sara
dc.contributor.authorMárquez Coello, María de las Mercedes 
dc.contributor.authorIllanes Álvarez, Francisco
dc.contributor.authorMárquez Ruiz, Denisse
dc.contributor.authorArizcorreta Yarza, Ana 
dc.contributor.authorGalán Sánchez, Fátima 
dc.contributor.authorMontiel, Natalia
dc.contributor.authorRodríguez Iglesias, Manuel Antonio 
dc.contributor.authorGirón González, José Antonio 
dc.contributor.otherBiomedicina, Biotecnología y Salud Públicaes_ES
dc.contributor.otherMedicinaes_ES
dc.date.accessioned2022-07-12T10:21:30Z
dc.date.available2022-07-12T10:21:30Z
dc.date.issued2022-01
dc.identifier.issn1948-5182
dc.identifier.urihttp://hdl.handle.net/10498/27161
dc.description.abstractLoss of follow-up or reinfections hinder the expectations of hepatitis C eradication despite the existence of highly effective treatments. Moreover, the elimination of the infection does not imply the reversion of those chronic alterations derived from the previous infection by hepatitis C virus (HCV). This review analyzes the risk factors associated with loss to follow-up in diagnosis or treatment, and the possibility of reinfection. Likewise, it assesses the residual alterations induced by chronic HCV infection considering the liver alterations (inflammation, fibrosis, risk of decompensation, hepatocellular carcinoma, liver transplantation) and, on the other hand, the comorbidities and extrahepatic manifestations (cryoglobulinemia, non-Hodgkin lymphoma, peripheral insulin resistance, and lipid, bone and cognitive alterations). Peculiarities present in subjects coinfected with human immunodeficiency virus are analyzed in each section.es_ES
dc.formatapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherBAISHIDENG PUBLISHING GROUP INCes_ES
dc.rightsAtribución-NoComercial 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.sourceWorld Journal of Hepatology, Vol. 14, Núm. 1, pp. 62-79es_ES
dc.subjectHepatitis C viruses_ES
dc.subjectSustained virological responsees_ES
dc.subjectDirect antiviral agentses_ES
dc.subjectHuman immunodeficiency viruses_ES
dc.subjectCirrhosis decompensationes_ES
dc.subjectHepatocarcinomaes_ES
dc.subjectExtrahepatic complicationses_ES
dc.titleHepatitis C: Problems to extinction and residual hepatic and extrahepatic lesions after sustained virological responsees_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.4254/WJH.V14.I1.62
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII)/PI19%2F01361/ES/INFECCION POR VIH, FORMACION DE NETS Y ATEROSCLEROSIS/es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/Junta de Andalucía//PI-0076-2017es_ES


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución-NoComercial 4.0 Internacional
Esta obra está bajo una Licencia Creative Commons Atribución-NoComercial 4.0 Internacional